ZA200305364B - Method for purifying 20(S)-camptothecin. - Google Patents
Method for purifying 20(S)-camptothecin. Download PDFInfo
- Publication number
- ZA200305364B ZA200305364B ZA200305364A ZA200305364A ZA200305364B ZA 200305364 B ZA200305364 B ZA 200305364B ZA 200305364 A ZA200305364 A ZA 200305364A ZA 200305364 A ZA200305364 A ZA 200305364A ZA 200305364 B ZA200305364 B ZA 200305364B
- Authority
- ZA
- South Africa
- Prior art keywords
- camptothecine
- purifying
- denotes
- vinyl
- crystals
- Prior art date
Links
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title claims description 47
- 238000000034 method Methods 0.000 title claims description 19
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 title 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 16
- 239000007858 starting material Substances 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 239000013078 crystal Substances 0.000 claims description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 12
- 239000003054 catalyst Substances 0.000 claims description 10
- 239000003880 polar aprotic solvent Substances 0.000 claims description 9
- 229910052723 transition metal Inorganic materials 0.000 claims description 8
- 150000003624 transition metals Chemical class 0.000 claims description 8
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 8
- 229920002554 vinyl polymer Polymers 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 239000008346 aqueous phase Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 229910052763 palladium Inorganic materials 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- -1 carboxylate salt Chemical class 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 claims description 2
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 claims description 2
- 150000002596 lactones Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- VGGNVBNNVSIGKG-UHFFFAOYSA-N n,n,2-trimethylaziridine-1-carboxamide Chemical compound CC1CN1C(=O)N(C)C VGGNVBNNVSIGKG-UHFFFAOYSA-N 0.000 claims description 2
- ZCOGQSHZVSZAHH-UHFFFAOYSA-N n,n-dimethylaziridine-1-carboxamide Chemical compound CN(C)C(=O)N1CC1 ZCOGQSHZVSZAHH-UHFFFAOYSA-N 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 241000060390 Nothapodytes nimmoniana Species 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 229910000000 metal hydroxide Inorganic materials 0.000 description 4
- 150000004692 metal hydroxides Chemical class 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000020477 pH reduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 1
- 241000759905 Camptotheca acuminata Species 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000209018 Nyssaceae Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000000686 lactone group Chemical group 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 125000002348 vinylic group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003799 water insoluble solvent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10106969A DE10106969C1 (de) | 2001-02-15 | 2001-02-15 | Verfahren zur Reinigung und zur Herstellung von 20(S)-Camptothecin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200305364B true ZA200305364B (en) | 2004-04-28 |
Family
ID=7674093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200305364A ZA200305364B (en) | 2001-02-15 | 2003-07-11 | Method for purifying 20(S)-camptothecin. |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1362051B1 (zh) |
| JP (1) | JP4467884B2 (zh) |
| KR (1) | KR100813087B1 (zh) |
| CN (1) | CN1228340C (zh) |
| AT (1) | ATE301124T1 (zh) |
| AU (1) | AU2002244711B2 (zh) |
| BG (1) | BG108064A (zh) |
| BR (1) | BR0207261A (zh) |
| CA (1) | CA2435372C (zh) |
| CZ (1) | CZ300671B6 (zh) |
| DE (2) | DE10106969C1 (zh) |
| EA (1) | EA005618B1 (zh) |
| EE (1) | EE05131B1 (zh) |
| ES (1) | ES2246389T3 (zh) |
| HK (1) | HK1064092A1 (zh) |
| HR (1) | HRP20030654A2 (zh) |
| HU (1) | HUP0303030A3 (zh) |
| IL (2) | IL157148A0 (zh) |
| MX (1) | MXPA03007194A (zh) |
| NO (1) | NO328106B1 (zh) |
| NZ (1) | NZ528039A (zh) |
| PL (1) | PL202135B1 (zh) |
| RS (1) | RS50496B (zh) |
| SK (1) | SK10192003A3 (zh) |
| UA (1) | UA74874C2 (zh) |
| WO (1) | WO2002064597A2 (zh) |
| ZA (1) | ZA200305364B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI396690B (zh) * | 2006-04-27 | 2013-05-21 | Yakult Honsha Kk | 喜樹鹼衍生物的製造方法 |
| CN102046634B (zh) * | 2008-05-29 | 2013-04-24 | 日本迈科洛生物制药有限公司 | 喜树碱衍生物的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5527913A (en) * | 1993-02-25 | 1996-06-18 | The Stehlin Foundation For Cancer Research | Methods for purifying camptothecin compounds |
-
2001
- 2001-02-15 DE DE10106969A patent/DE10106969C1/de not_active Expired - Fee Related
-
2002
- 2002-02-09 NZ NZ528039A patent/NZ528039A/en unknown
- 2002-02-09 BR BR0207261-0A patent/BR0207261A/pt not_active Expired - Fee Related
- 2002-02-09 ES ES02712902T patent/ES2246389T3/es not_active Expired - Lifetime
- 2002-02-09 KR KR1020037010605A patent/KR100813087B1/ko not_active IP Right Cessation
- 2002-02-09 DE DE50203824T patent/DE50203824D1/de not_active Expired - Lifetime
- 2002-02-09 AT AT02712902T patent/ATE301124T1/de active
- 2002-02-09 CZ CZ20032211A patent/CZ300671B6/cs not_active IP Right Cessation
- 2002-02-09 AU AU2002244711A patent/AU2002244711B2/en not_active Ceased
- 2002-02-09 PL PL362128A patent/PL202135B1/pl not_active IP Right Cessation
- 2002-02-09 CN CNB028049918A patent/CN1228340C/zh not_active Expired - Fee Related
- 2002-02-09 JP JP2002564528A patent/JP4467884B2/ja not_active Expired - Lifetime
- 2002-02-09 IL IL15714802A patent/IL157148A0/xx active IP Right Grant
- 2002-02-09 RS YUP-614/03A patent/RS50496B/sr unknown
- 2002-02-09 EE EEP200300389A patent/EE05131B1/xx not_active IP Right Cessation
- 2002-02-09 MX MXPA03007194A patent/MXPA03007194A/es active IP Right Grant
- 2002-02-09 HU HU0303030A patent/HUP0303030A3/hu unknown
- 2002-02-09 EA EA200300837A patent/EA005618B1/ru not_active IP Right Cessation
- 2002-02-09 SK SK1019-2003A patent/SK10192003A3/sk unknown
- 2002-02-09 WO PCT/EP2002/001375 patent/WO2002064597A2/de active IP Right Grant
- 2002-02-09 CA CA2435372A patent/CA2435372C/en not_active Expired - Lifetime
- 2002-02-09 EP EP02712902A patent/EP1362051B1/de not_active Expired - Lifetime
- 2002-09-02 UA UA2003098461A patent/UA74874C2/uk unknown
-
2003
- 2003-07-11 ZA ZA200305364A patent/ZA200305364B/en unknown
- 2003-07-29 IL IL157148A patent/IL157148A/en not_active IP Right Cessation
- 2003-08-06 BG BG108064A patent/BG108064A/bg active Pending
- 2003-08-13 HR HR20030654A patent/HRP20030654A2/hr not_active Application Discontinuation
- 2003-08-14 NO NO20033614A patent/NO328106B1/no not_active IP Right Cessation
-
2004
- 2004-09-08 HK HK04106806A patent/HK1064092A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU664830B2 (en) | Water soluble camptothecin analogues, processes and methods | |
| EP3172207B1 (en) | A process for the preparation of cgmp-phosphodiesterase inhibitor and oral pharmaceutical formulation comprising tadalafil co-precipitates | |
| US20030013897A1 (en) | Process for preparing piperonal | |
| ZA200305364B (en) | Method for purifying 20(S)-camptothecin. | |
| CN105061428B (zh) | 一种精制他达拉非的方法 | |
| US6476225B2 (en) | Process for purifying 20(S)-camptothecin | |
| US4150038A (en) | Conversion of hesperidin into hesperetin | |
| US20040225129A1 (en) | Process for preparing and purifying 1,7'-dimethyl-2'-propyl-2,5'-bi-1H-benzimidazole | |
| US12091419B2 (en) | Method for preparing dihydroartemisinin bulk drug in single process | |
| CN110734443A (zh) | 一种他达拉非有关物质i的制备方法 | |
| CA2509561A1 (en) | Synthesis of heteroaryl acetamides | |
| EP1253149B1 (en) | Sulfate salt of quinolonecarboxylic acid derivative and use thereof | |
| CN112679513B (zh) | 一种制备曲贝替定的关键中间体的方法 | |
| CN118063454A (zh) | 一种二氢小檗碱的制备方法 | |
| CN116891433A (zh) | 罗沙司他的制备方法 | |
| CN118221681A (zh) | 一种别嘌醇的制备方法 | |
| HU183171B (en) | New process for producing indolo-bracket-2,3-c-bracket closed-quinazolino-bracket-3,2-a-bracket closed-pyridin-5-ones | |
| WO2006046096A2 (en) | A polymorphic form of narwedine and its use in the synthesis of galantamine |